1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63379B92CBF84D79285256EC5004ACC7B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/sample-managing-pharmaceutical-sales-force-incentives-for-high-performance?opendocument
18
19opendocument
20107.23.176.162
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25RAS




Products & Services

SAMPLE: Managing Pharmaceutical Sales Force Incentives for High Performance

Whitepaper Image

ID: BEB-06


Pages/Slides: 8


Published: Pre-2013


Delivery Format: PDF


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Download White Paper

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS

This research sample benchmarks how pharmaceutical companies drive high performance by their sales forces at six leading pharmaceutical companies. Metrics include sales incentive compensation structures and capped versus uncapped incentives. This research originated with the Best Practices, LLC Business Excellence Board (BEB.)

To view the full study this summary came from, click here.

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Health Care


Companies Profiled:
AstraZeneca; Roche; Pfizer; Merck; Eli Lilly; GlaxoSmithKline